NASDAQ:DVAX - Dynavax Technologies Stock Price, News, & Analysis

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The biopharmaceutical company earned $5.77 million during the quarter, compared to analyst estimates of $5.95 million. Dynavax Technologies had a negative net margin of 1,156.11% and a negative return on equity of 190.84%. The business's revenue for the quarter was up 3294.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.63) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Dynavax Technologies.

4 brokerages have issued twelve-month price objectives for Dynavax Technologies' shares. Their predictions range from $25.00 to $30.00. On average, they expect Dynavax Technologies' stock price to reach $27.6667 in the next year. This suggests a possible upside of 335.7% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Press coverage about DVAX stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.

Some companies that are related to Dynavax Technologies include Zogenix (ZGNX), Zai Lab (ZLAB), Prestige Consumer Healthcare (PBH), Nabriva Therapeutics (NBRV), Madrigal Pharmaceuticals (MDGL), Innoviva (INVA), Endo International (ENDP), Heron Therapeutics (HRTX), Cambrex (CBM), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Apellis Pharmaceuticals (APLS) and Phibro Animal Health (PAHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), Kite Pharma (KITE), United Continental (UAL), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.51%), Federated Investors Inc. PA (5.86%), Chicago Capital LLC (3.98%), Eagle Asset Management Inc. (3.74%), Bain Capital Public Equity Management LLC (1.94%) and FMR LLC (1.67%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, DekaBank Deutsche Girozentrale, Northern Trust Corp, Gables Capital Management Inc., Patriot Financial Group Insurance Agency LLC, Jane Street Group LLC and California State Teachers Retirement System. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Bain Capital Public Equity Management LLC, Rhenman & Partners Asset Management AB, Macquarie Group Ltd., Marshall Wace North America L.P., Federated Investors Inc. PA, BlackRock Inc. and Assenagon Asset Management S.A.. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $6.35.

Dynavax Technologies has a market capitalization of $413.16 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]